Acadia Pharmaceuticals ACAD
NASDAQ ACAD
$22.18 -3.25 (-12.78%)
At close: Sep 24, 2026 · 4:00 PM EDT

Acadia Pharmaceuticals (ACAD) Net Income towards Common Stockholders (2010 - 2026)

Acadia Pharmaceuticals (ACAD) posted Net Income towards Common Stockholders of $31.5 million for Q2 2026, up 766.1% on a QoQ basis from $3.6 million in Q1 2026, and up 18.13% year-over-year from $26.7 million in Q2 2025.

Analysis

Acadia Pharmaceuticals (ACAD) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

Acadia Pharmaceuticals has reported Net Income towards Common Stockholders for 17 years, with the latest figure at $31.5 million in Q2 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 18.13% year-over-year to $31.5 million in Q2 2026; TTM through Jun 2026 was $380.5 million, a 71.27% increase from a year earlier, with the FY2025 full-year figure at $391.0 million, up 72.66% from the prior year.
  • Net Income towards Common Stockholders was $31.5 million for Q2 2026 at Acadia Pharmaceuticals, up from $3.6 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $273.6 million in Q4 2025, with the low at -$113.1 million in Q1 2022.
  • Average Net Income towards Common Stockholders over 5 years is $23.5 million, with a median of $17.8 million recorded in 2024.
  • The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders sank 139.49% in 2023, then surged 2897.22% in 2024.
  • Over 5 years, Net Income towards Common Stockholders stood at $5.7 million in 2022, then jumped by 706.43% to $45.8 million in 2023, then surged by 213.87% to $143.7 million in 2024, then soared by 90.32% to $273.6 million in 2025, then sank by 88.49% to $31.5 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at $31.5 million (Q2 2026), $3.6 million (Q1 2026), and $273.6 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Johnson & Johnson 649.01 Bn 628.25 Bn 17.26 Bn 5.53 Bn
2 AbbVie 468.55 Bn 462.03 Bn 12.70 Bn 3.62 Bn
3 Merck 365.49 Bn 358.40 Bn 12.21 Bn -1.34 Bn
4 Novartis Ag 272.39 Bn 265.10 Bn 11.24 Bn 3.26 Bn
5 Astrazeneca 253.18 Bn 247.96 Bn 12.86 Bn 2.51 Bn
6 Amgen 219.53 Bn 205.54 Bn 7.24 Bn 2.38 Bn
7 Gilead Sciences 187.85 Bn 184.59 Bn 6.22 Bn -10.50 Bn
8 Pfizer 160.56 Bn 149.16 Bn 10.94 Bn -238.00 Mn
9 Vertex Pharmaceuticals 130.81 Bn 122.96 Bn 2.84 Bn 1.10 Bn
10 Acadia Pharmaceuticals 4.38 Bn 3.42 Bn 279.64 Mn 31.50 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 31.50 Mn
Mar 31, 2026 3.64 Mn
Dec 31, 2025 273.57 Mn
Sep 30, 2025 71.78 Mn
Jun 30, 2025 26.67 Mn
Mar 31, 2025 18.99 Mn
Dec 31, 2024 143.74 Mn
Sep 30, 2024 32.77 Mn
Jun 30, 2024 33.39 Mn
Mar 31, 2024 16.56 Mn
Dec 31, 2023 45.80 Mn
Sep 30, 2023 -65.18 Mn
Jun 30, 2023 1.11 Mn
Mar 31, 2023 -43.02 Mn
Dec 31, 2022 5.68 Mn
Sep 30, 2022 -27.22 Mn
Jun 30, 2022 -34.04 Mn
Mar 31, 2022 -113.10 Mn
Dec 31, 2021 -7.56 Mn
Sep 30, 2021 -14.46 Mn
API Access

Acadia Pharmaceuticals Net Income towards Common Stockholders API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=ACAD&period=max&api_key=YOUR_API_KEY